MGNX News and Press, MacroGenics Inc. From 04/05/24

2024-04-05 02:31:21 ET Summary Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. ...

2024-04-04 13:06:43 ET More on Mid-day movers & stocks. Seeking Alpha’s Quant Rating on Barinthus Biotherapeutics Historical earnings data for Barinthus Biotherapeutics Financial information for Barinthus Biotherapeutics Seeking Alpha’s Quan...

MacroGenics, Inc. (NASDAQ: MGNX) is one of today's top gainers. The company's shares have moved 28.68% on the day to $17.59. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MAR...

A look at the top 10 most actives in the United States WiSA Technologies Inc. (WISA) rose 0.8% to $0.0245 on volume of 49,663,616 shares TC BioPharm (Holdings) plc (TCBP) rose 134.2% to $3.045 on volume of 39,956,892 shares Nikola Corporation (NKLA) rose 8.1% to $0.963899 on volume of 31,...

2024-04-04 06:56:09 ET More on MacroGenics MacroGenics, Inc. (MGNX) Q4 2023 Earnings Call Transcript MacroGenics: Evaluating Its Buy Status After A 200% Surge On Prostate Cancer Prospects MacroGenics: Trying To Build A Better Everything MacroGenics Q4 2023 Ea...

2024-04-04 06:00:04 ET Stephen Willey from Stifel Nicolaus issued a price target of $29.00 for MGNX on 2024-04-04 04:40:00. The adjusted price target was set to $29.00. At the time of the announcement, MGNX was trading at $13.67. The overall price target consensus is at ...

2024-04-03 17:24:42 ET Gainers: Signature Bank ( OTC:SBNY ) +10% . MacroGenics ( MGNX ) +9% . Simulations Plus ( SLP ) +7% . Annexon ( ANNX ) +6% . 2seventy  ( TSVT ) +5% . Losers: Cadiz ( CDZIP ) -11% . ...

Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstract Company plans to provide updated interim data, including safety and preliminary efficacy, by May 31 Company plans to prov...

2024-03-16 23:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-08 00:30:17 ET Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q4 2023 Earnings Call Mar 07, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q4 2023 Earnings Call Transcript